论文部分内容阅读
美国胃肠肿瘤研究组对1975年7月至1979年8月经手术切除的结肠癌行前瞻性随机辅助治疗试验,以确定可否提高存活率。 621例Dukes分期为B_2(穿透浆膜,无淋巴结转移)C_1(侵及淋巴结1～4个)及C_2(侵及淋巴结5个以上)的结肠癌根治切除术后的病人,除49例因不合规定等原因除外,572例按肿瘤分期、部位、(?)润程度及患者性别、年龄等随机分为4组:化疗组:144例每5周1次交替应用下列两组药物:①5FU325mg/M~2/d,静注,连续5天,于第1天并加用甲基罗氮芥(semustine)130mg/M~2,口服;②5 FU
The American Gastrointestinal Tumor Research Group conducted a prospective randomized adjuvant therapy trial of surgically resected colon cancer from July 1975 to August 1979 to determine whether the survival rate could be improved. 621 patients with Dukes stage B_2 (through serosa, no lymph node metastasis) C_1 (invasion of lymph nodes 1-4) and C_2 (invasion of lymph nodes more than 5) after radical resection of colon cancer, except for 49 cases Irrespective of reasons such as irregularities, 572 patients were randomly divided into 4 groups according to the tumor stage, site, (?) Run extent and patient’s gender, age, etc.: Chemotherapy group: 144 cases alternately applied the following two groups of drugs every 5 weeks: 15FU 325mg/ M~2/d, intravenously, for 5 consecutive days, on the first day, plus semustine 130mg/M~2, orally; 25 FU